Bayer flags strong results of prostate cancer drug

June 6, 2011

German chemical and pharmaceutical group Bayer said Monday that its Alpharadin treatment for prostate cancer has shown positive results in advanced trials.

Bayer developed Alpharadin with the Norwegian lab Algeta and tested it on 922 people in Phase III trials, a statement said.

Those on the treatment lived an average 14 months after the course began, compared with an average of 11.2 months for those given a placebo, it added.

The tests were abandoned early to allow the latter to be given Alpharadin as well.

It has not yet been approved for general sale but Bayer has placed strong hopes in the compound, radium-223 chloride, which attacks in bones.

"Around 90 percent of men with advanced prostate cancer have which are the main cause of disability and death in this disease," the statement said.

Prostate cancer is the most frequent form of cancer among men in Northern Europe and the United States. In 2008, an estimated 903,000 men had worldwide and 250,000 died from the disease, Bayer said.

The news was welcomed on Frankfurt's stock exchange, where Bayer shares gained 1.98 percent to 56.53 euros to lead gainers on the DAX index which was 0.27 percent lower overall.

Related Stories

Recommended for you

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.